Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
Clinical trial NCT06962449 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06962449
- Sponsor
- Shanghai Chest Hospital
- Status
- ENROLLING_BY_INVITATION
- Study type
- OBSERVATIONAL
- Start date
- 2024-08-16
- Primary completion
- 2025-06-30
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.